Original language | English (US) |
---|---|
Pages (from-to) | 717-735 |
Number of pages | 19 |
Journal | Journal of Hepatology |
Volume | 64 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2016 |
Keywords
- Acute on chronic liver failure
- Cardiopulmonary dysfunction
- Cirrhosis
- Hematologic dysfunction
- Hepatic encephalopathy
- Hepatorenal syndrome
- Infectious disease
- Intensive care
- Renal dysfunction
ASJC Scopus subject areas
- Hepatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Hepatology, Vol. 64, No. 3, 01.03.2016, p. 717-735.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Management of the critically ill patient with cirrhosis
T2 - A multidisciplinary perspective
AU - Nadim, Mitra K.
AU - Durand, Francois
AU - Kellum, John A.
AU - Levitsky, Josh
AU - O'Leary, Jacqueline G.
AU - Karvellas, Constantine J.
AU - Bajaj, Jasmohan S.
AU - Davenport, Andrew
AU - Jalan, Rajiv
AU - Angeli, Paolo
AU - Caldwell, Stephen H.
AU - Fernández, Javier
AU - Francoz, Claire
AU - Garcia-Tsao, Guadalupe
AU - Ginès, Pere
AU - Ison, Michael G.
AU - Kramer, David J.
AU - Mehta, Ravindra L.
AU - Moreau, Richard
AU - Mulligan, David
AU - Olson, Jody C.
AU - Pomfret, Elizabeth A.
AU - Senzolo, Marco
AU - Steadman, Randolph H.
AU - Subramanian, Ram M.
AU - Vincent, Jean Louis
AU - Genyk, Yuri S.
N1 - Funding Information: MKN is a consultant for Ikaria and Baxter and an Advisor and on the Data and Safety Monitoring board for La Jolla Pharmaceutical Company. FD is a consultant for Astellas, Novartis, Gilead and Bristol-Myers Squibb and has received research funding from Gilead and Astellas Pharma. JAK is a consultant for Fresenius, Baxter, Grifols, Astute Medical, Alere, AM Pharma, Spectral, Cytosorbents, Alung, Atox Bio and Bard, has received grant support from Gambro, Baxter, Bard, Astute Medical, Alere, Spectral, Grifols, Cytosorbents, Kaneka, Atox Bio and has licensing agreement with Astute Medical, Spectral and Cytosorbents. JGO is a consultant for Grifols, Gilead, Abbvie, Novartis, Astellas, Fisher Scientific and has received grant support from Grifols. PG is a consultant and on the advisory board for Ferring Pharmaceuticals and Ikaria and has research funding from Grifols and Sequana Medical. JSB is a consultant for Salix, Norgine and Grifols. RJ has received research funding from Vital Therapies, has served on Scientific Advisory Board for Conatus Pharma, received lecture fees from Gambro, has ongoing research collaboration with Gambro, Grifols, is the Principal Investigator of an Industry sponsored study (Sequana Medical), inventor for a drug, L-ornithine phenyl acetate which UCL has licensed to Ocera Therapeutics and the founder of UCL spin-out company Yaqrit ltd. and Cyberliver ltd. SHC is a consultant and has received research funding from Vital Therapies. MGI has research support from Anolinx, Chimerix, Gilead, Glaxo Smith Klein, Viro Pharma, is a consultant for Biota, Chimerix, Farmark, Genentech/Roche, Shionogi, Adamas, BioCryst, Cellex, Clarassance, Glaxo Smith Klein, GenMarkDx, Romark, Toyama/MediVector, NexBio, Theraclone, Vertex and on the Data and Safety Monitoring Board for Abbott, Jansen/Vertex. JCO is a consultant for Baxter. YSG is a consultant for Baxter. Funding Information: This conference was supported by unrestricted educational grants from Ikaria, Salix Pharmaceuticals, Gilead, Grifols, Baxter Healthcare Corporation and Astellas Pharma France. None of the companies that provided financial support for this meeting were involved in any way in the organization of the meeting, the decision regarding invited faculty, the design and contents of the meeting, the collection, management, analysis, and interpretation of the data, and preparation, review, or approval of the manuscript. None of the authors received any honorarium for their participation in this meeting.
PY - 2016/3/1
Y1 - 2016/3/1
KW - Acute on chronic liver failure
KW - Cardiopulmonary dysfunction
KW - Cirrhosis
KW - Hematologic dysfunction
KW - Hepatic encephalopathy
KW - Hepatorenal syndrome
KW - Infectious disease
KW - Intensive care
KW - Renal dysfunction
UR - http://www.scopus.com/inward/record.url?scp=84958882811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958882811&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2015.10.019
DO - 10.1016/j.jhep.2015.10.019
M3 - Article
C2 - 26519602
AN - SCOPUS:84958882811
SN - 0168-8278
VL - 64
SP - 717
EP - 735
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 3
ER -